Related Experiment Video

Updated: Jun 19, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Expression of mTOR protein and its clinical significance in endometrial cancer

Jae Hong No1, Yong-Tark Jeon, In-Ae Park

  • 1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|October 1, 2009
PubMed
Abstract

Insights

Mammalian target of rapamycin (mTOR) expression is infrequent in endometrial cancer and correlates with cyclooxygenase-2 (COX-2) overexpression. This suggests careful patient selection is needed for mTOR inhibitor therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Mammalian target of rapamycin (mTOR) is crucial in carcinogenesis and a target for anticancer drugs.
  • Phosphatase and tensin homologue (PTEN) mutations, common in endometrial cancer, negatively regulate mTOR.
  • Understanding mTOR expression in endometrial cancer is vital for targeted therapy development.

Purpose of the Study:

  • To evaluate the expression of mTOR in endometrial cancer.
  • To investigate the relationship between mTOR expression and clinicopathological characteristics.
  • To analyze the association of mTOR with cyclooxygenase-2 (COX-2) and p53 expression patterns.

Main Methods:

  • Immunohistochemical analysis of mTOR was performed on 141 endometrial carcinoma tissue specimens.
  • Results were correlated with clinicopathological features and expression of COX-2 and p53.

Main Results:

  • mTOR overexpression was observed in 7.1% of endometrial cancer patients.
  • mTOR expression significantly correlated with older age, menopausal status, and COX-2 expression.
  • COX-2 was identified as the sole independent factor associated with mTOR expression; no correlation with prognostic factors was found.

Conclusions:

  • mTOR expression is infrequent in endometrial cancer and linked to COX-2 overexpression.
  • Targeted therapy using mTOR inhibitors may require careful patient selection based on biomarkers like COX-2.
  • Further research into the mTOR pathway in endometrial cancer is warranted.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...